# US 2019/0316139 A1 · Methods and Compositions for Selecting siRNA of Improved Functionality

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316139 A1
- Document ID: US20190316139A1
- Status: Published application
- Kind: A1
- Application number: 16/256,933
- Filed: 2019-01-24
- Published: 2019-10-17
- Earliest claimed: 2002-11-14
- Assignees: Thermo Fisher Scientific Inc.
- Applicants: Thermo Fisher Scientific Inc.
- Inventors: Anastasia Khvorova; Angela Reynolds; Devin Leake; William Marshall; Steven Read; Stephen Scaringe
- Web page: https://patentgrep.com/patent/US20190316139A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- C07K 14/745: Blood coagulation or fibrinolysis factors
- C12N 15/1048: {SELEX}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/8218: {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
- C12Y 113/12007: Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
- C12Y 502/01008: Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2320/10: in screening processes
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2320/13: in a process of directed evolution, e.g. SELEX, acquiring a new function
- C12N 2330/31: Libraries, arrays
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for F12.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

An siRNA molecule comprising a duplex region of 18 to 30 base pairs in length, wherein
the siRNA molecule targets a F12 (Factor XII) gene; and
the duplex region is of two separate strands of a sense strand and an antisense strand; and
the siRNA molecule comprises at least one of the following:
(1) a low GC content, preferably between about 30-52%,
(2) at least 2, preferably at least 3 A or U bases at positions 15-19 on the sense strand,
(3) an A base at position 19 of the sense strand,
(4) an A base at position 3 of the sense strand,
(5) a U base at position 10 of the sense strand,
(6) an A base at position 14 of the sense strand,
(7) a base other than C at position 19 of the sense strand,
(8) a base other than G at position 13 of the sense strand,
(9) a Tm that is preferably not stable at greater than 50° C.
(10) a base other than U at position 5 of the sense strand, and
(11) a base other than A at position 11 of the sense strand.

### Claim 17 (depends on 16)

The siRNA molecule of claim 16, where the 3′ end of the sense strand is position 19.

### Claim 18 (depends on 16)

The siRNA molecule of claim 16, wherein the siRNA molecule comprises a base other than C at position 19 of the sense strand, and a base other than G at position 13 of the sense strand.

### Claim 19 (depends on 16)

The siRNA molecule of claim 16, wherein the sense strand comprises a sequence homologous to one of SEQ ID NO:438-504, 506, 507, or 508.

### Claim 20 (depends on 16)

The siRNA molecule of claim 16, wherein the antisense strand and the sense strand are each 20 to 30 bases in length.

### Claim 21 (depends on 16)

The siRNA molecule of claim 16, wherein the siRNA molecule has at least one overhang region.

### Claim 22

A chemically synthesized double stranded siRNA molecule, wherein:
(a) each strand of the double stranded siRNA molecule is between 18 and 30 bases in length; and
(b) one strand of the siRNA molecule comprises a sequence that is the complement of one of SEQ ID NO:438-504, 506, 507, or 508.

### Claim 23 (depends on 22)

The chemically synthesized double stranded siRNA molecule of claim 22 wherein each strand of the siRNA molecule is 20-30 nucleotides in length.

### Claim 24 (depends on 16)

The siRNA molecule of claim 16, wherein the siRNA molecule comprises a 2′-position sugar modification.

### Claim 25 (depends on 24)

The siRNA molecule of claim 24, wherein the 2′-position sugar modification is selected from the group consisting of H, OR, R, halo, SH, SR, NH2, NHR, NR2, or CN, wherein R is an alkyl moiety.

### Claim 26 (depends on 16)

The siRNA molecule of claim 16, wherein the siRNA molecule comprises a non-natural phosphodiester linkage selected from a methylphosphonate, a phosphorothioate and a peptide.
